Inactive Instrument

Gracell Biotechnologies Inc.

Equities

GRCL

US38406L1035

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Global markets live: Booking, Diageo, AT&T, Nvidia, UBS... Our Logo
EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track" AN
AstraZeneca Completes Gracell Biotechnologies Acquisition MT
Stifel Downgrades Gracell Biotechnologies to Hold From Buy, Trims Price Target to $10.25 From $11 MT
AstraZeneca completes acquisition of Gracell Biotechnologies CF
AstraZeneca Closes Purchase of Gracell Biotechnologies MT
Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Composite Index CI
AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. from a group of shareholders. CI
Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Biotechnology Index CI
Gracell Biotechnologies Cleared for Early-Stage Trial of Prospective Multiple Myeloma Treatment MT
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T Gc012F as Early-Line Treatment of Multiple Myeloma CI
AstraZeneca to Buy China’s Gracell For $1.2 Billion MT
Fusion Pharmaceuticals an 'Attractive' Takeover Target Following Recent Radiopharma Deals, Oppenheimer Says MT
Stocks start week higher as 2024 draws to close AN
Wells Fargo Downgrades Gracell Biotechnologies to Equalweight From Overweight, $10 Price Target MT
Dpa-AFX Overview: COMPANIES from 27.12.2023 - 15:15 DP
Stocks hold onto gains amid US rate cut hopes AN
European Midday Briefing : Falling U.S. Inflation Continues to Support Sentiment DJ
Year-end rate-cut optimism, miners push UK stocks higher RE
FTSE 100 gains led by miners and industrials AN
AstraZeneca buys Gracell to "enrich" cell therapy pipeline AN
AstraZeneca: agreement to acquire Gracell CF
AstraZeneca buys Gracell Biotech; COPL CEO resigns AN
Piper Sandler Downgrades Gracell Biotechnologies to Neutral From Overweight, Raises Price Target to $10 From $9 MT
EMEA Morning Briefing : Stock Futures Higher to Start Last Trading Week of Year DJ
Chart Gracell Biotechnologies Inc.
More charts
Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical company focused on discovering and developing cell therapies for the treatment of cancers. The Company is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The Company is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.
More about the company
  1. Stock
  2. Equities
  3. Stock Gracell Biotechnologies Inc. - Nasdaq
  4. News Gracell Biotechnologies Inc.
  5. Gracell Biotechnologies : Wells Fargo Starts Gracell Biotechnologies at Overweight With $33 Price Target